Statement of Translational Relevance
In this study we assess the impact of combining gemtuzumab ozogamicin (GO) with conventional chemotherapy in pediatric patients with FLT3/ITD positive AML and show that the addition of GO in induction results in reduction of relapse. This anti-leukemic effect was even more pronounced in high allelic ratio FLT3/ITD patients. Ours is the first study to examine the impact of CD33 targeting and GO in pediatric FLT3/ITD AML and assess its impact by allelic ratio, which is recognized as a marker of poor prognosis. This high-risk group of patients is in need of new therapeutic strategies as a significant number patients experience relapse despite intensive chemotherapy and hematopoietic stem cell transplant.
Our study finds that FLT3/ITD patients experience significant benefit from CD33 AAML0531 confirmed the safety and benefit of adding GO to intensive chemotherapy in pediatric AML. (6, 12) Therapy intensification and advancements in supportive care have led to improvement in overall outcomes in pediatric AML. However, patients with FLT3/ITD have a poor prognosis with chemotherapy alone, especially those with a high allelic ratio (ITD-AR; >0.4) of mutant to wild type FLT3. (13) (14) (15) (16) (17) (18) Although allogeneic hematopoietic stem cell transplant (HCT) increases the survival to approximately 65% for this cohort, alternative therapeutic approaches are needed to improve long-term survival in a significant number of children with this lesion. (13, 19) Because the limits to which conventional treatment can be intensified have been reached, the use of alternative approaches such as immunotherapy are necessary to further improve outcomes. In this study, we investigated the impact of CD33 targeting with GO in FLT3/ITD patients as a method to improve outcomes for this high-risk group of patients.
Methods

Patients and treatment
Pediatric patients (ages 1 month to 30 years) with de novo AML enrolled on the COG phase III pilot study AAML03P1 and the subsequent phase III trial 
Statistical analysis
The significance of observed difference in proportions was tested using There were no significant differences by age, gender, race, ethnicity, extramedullary involvement, cytogenetic features, presenting white blood cell count, and bone marrow blast percentages between the GO and No-GO cohorts (Table 1 ). There were significantly more patients with NPM1 mutations in the No-GO vs. GO cohort (p=0.01). Although NPM1 mutations have subsequently been demonstrated to be a low-risk mutation and confer a favorable prognosis,(23, 24) patients treated on AAML03P1 and AAML0531 were not stratified by NPM1 status and some received HCT in first CR per protocol stratification. There were no significant differences between FLT3/ITD high vs. low allelic ratios between the two treatment cohorts (Table 1) .
Patients in the GO cohort received the initial dose of GO during induction I, we therefore analyzed the impact of GO on CR rates at the end of induction (EOI) I.
After the initial induction course, patients with FLT3/ITD had a CR rate of 64% vs.
Research. Post-induction clinical outcome was evaluated based on induction exposure to GO. FLT3/ITD patients treated with GO had a reduction in RR of 37 ± 12% vs. 59 ± 16% for the No-GO cohort (p=0.02; Figure 1A ). However, this GO associated improvement in relapse did not translate into an improvement in survival, as the GO vs. No-GO cohorts had a DFS of 47 ± 12% vs. 41± 15% (p=0.5; Figure 1B) and an OS of 50 ± 10% vs. 49 ± 13%, respectively (p=0.74). Evaluation of TRM demonstrated that patients who received GO had a significantly higher rate of TRM compared to the No-GO recipients (16 ± 9% vs. 0%; p=0.008; Figure 1C ).
In univariable and multivariable cox regression analyses that included treatment arm, NPM1 mutation status, diagnostic white blood cell count, and race, treatment with GO was associated with lower RR compared to No-GO (HR 0.4, p=0.01; Supplementary Table 1 ). There were no differences among the GO vs. in the GO arm, there was no convergence for further analysis, again demonstrating higher TRM for patients treated with GO.
GO and hematopoietic stem cell transplant
Our group and others have demonstrated the poor prognostic impact of high ITD-AR on outcome, and that these patients may benefit from intensification of consolidation therapy with allogeneic HCT. (13, 15, 25) As a result, an amendment was introduced into AAML0531 that allocated FLT3/ITD patients with high ITD-AR to the high risk arm of therapy and to receive allogeneic HCT in first CR. Of the 58 patients with FLT3/ITD who received HCT in first CR, 33 had received induction GO and 25 were treated on the No-GO arm. Cumulative incidence of relapse for the GO recipients was 22 ± 15% vs. 56 ± 21% for the No-GO cohort (p=0.003; Figure 2A ) with a corresponding DFS of 56 ± 18% vs.
40 ± 20% (p=0.09; Figure 2B ). TRM for GO recipients compared to No-GO recipients was 22 ± 15% vs. 4 ± 8% (p=0.08; Figure 2C ). The OS for patients in the GO and No-GO cohorts was 65 ± 17% vs. 49 ± 22% (p=0.21).
Among FLT3/ITD patients who received consolidation chemotherapy alone (n=57), patients who received GO (n=25) vs. No-GO (n=22) had similar RR (43 ± 17% vs. 58 ± 23%, p=0.28), OS (59 ± 17% vs. 60% ± 22%, p=0.90), DFS (45 ± 17% vs. 42 ± 22%; p=0.80), and TRM (12 ± 11% vs. 0%; p=0.11; Supplementary 
Impact of GO and high allelic ratio FLT3/ITD
We evaluated the role of GO in this high-risk cohort with high ITD-AR who underwent HCT in first CR (n=41) according to treatment with induction GO (n=26) versus No-GO (n=15). Post transplant RR in GO recipients was 15 ± 15% vs. 53 ± 27% for the No-GO cohort (p=0.007; Figure 3A ) with a corresponding DFS of 65 ± 19% vs. 40 ± 25% (p=0.08; Figure 3B ) and OS of 68 ± 19% vs. 51 ± 27% (p=0.33). The TRM among GO vs. No-GO recipients treated with HCT was 19 ± 16% vs. 7 ± 13% (p=0.30; Figure 3C ). Evaluation of the effect of GO on high ITD-AR patients who did not receive HCT demonstrated that GO recipients (n=17) had a RR 47 ± 25% vs. 64 ± 36% for the No-GO cohort (n=10; p=0.42), with a corresponding DFS of 47 ± 24% vs. 36 ± 32%, (p=0.66), OS of 64 ± 24% vs. 56 ± 33% (p=0.67), and a TRM of 6 ± 12% vs. 0% respectively (p=0.44).
We analyzed outcomes of low AR (≤0.4) patients and found GO recipients (n=25) had an OS of 53 ± 22% vs. 58 ± 22% for the No-GO cohort (n=22; p=0.99), with a corresponding DFS of 34 ± 21% vs. 44 ± 22% (p=0.87) and a RR of 42 ± 22% vs 56% ± 22% (p=0.19; Supplementary Table 2) . High TRM was again noted in GO recipients compared to No-GO (24 ± 20% vs. 0%; p=0.04). Most patients with low AR received consolidation chemotherapy alone so these patients were not stratified further according to consolidation therapy.
GO and treatment-related mortality
Research. The increase in TRM that was seen in the GO arm for FLT3/ITD patients was further analyzed, especially with regard to initial concerns that GO was associated with increased incidence of post-HCT sinusoidal obstructive syndrome (SOS). Among all patients treated on AAML03P1 and AAML0531, 31 had SOS of any grade that occurred after HCT. Among FLT3/ITD patients, 8 had SOS of any grade (GO, n=6; No-GO, n=2), although the overall numbers were too low to draw any significant conclusions. In almost all cases, SOS was not fatal. However, in 3 patients treated on the 2 studies, SOS was listed as the cause or significant contributing cause of death and occurred in the first 30 days post-HCT. Of the 3 patients, 2 were FLT3/ITD patients who received GO and 1 was a FLT3 wild-type patient who did not receive GO.
In an analysis of the causes of TRM among FLT3/ITD patients, we identified 14 cases of TRM in the GO cohort, equally divided between no-HCT (n=7) and HCT (n=7) recipients. Infections were the major cause of TRM among GO recipients (n=9, 64%). Among the no-HCT recipients, 6 of 7 deaths were attributed to infection, with 1 of these deaths occurring more than 1000 days after the end of the intensification course II, which included the last dose of GO. Among the HCT recipients in the GO cohort, infections were the cause of death in 4 patients.
TRM was attributed to SOS in 1 patient and was the primary contributing cause where no primary cause was listed in 1 other patient. Among the GO cohort who received HCT, 5 of 7 deaths occurred more than 100 days from HCT and more than 250 days from the end of the induction I course which contained the only Table 3 ).
There were no differences between the cohorts for all grade 3 or higher toxicities (CTC v3.0 Toxicity) for any of the treatment cycles, including among patients who Table 4 ). Importantly, there were no differences among grade 3 or higher infection rates, incidence of hemorrhage, or liver dysfunction between both cohorts (Supplementary Table 4 ).
Discussion
In this retrospective study of de novo pediatric FLT3/ITD AML patients, we found that although the addition of GO to standard chemotherapy did not improve the initial CR rate, exposure to GO during induction led to significant reduction in relapse in this high-risk population. Furthermore, the impact of GO persisted into consolidation HCT, where those who had received induction GO had a significantly lower rate of relapse post HCT. The disease benefit was most pronounced in high ITD-AR patients, the cohort with the highest risk disease. 
high-risk cohort may be achieved with the use of induction GO followed by HCT in first CR.
The data we present is consistent with the increasing evidence from adult and pediatric clinical trials that targeting CD33 is a promising therapeutic strategy in AML and can enhance the effects of conventional chemotherapy and allogeneic HCT. (8, 10, 12) A recent meta-analysis on the use of GO in AML found that GO was associated with reduction in RR and improved OS, with the most significant survival benefit in patients with good and intermediate cytogenetic risk The single dose GO regimen utilized in the COG trials was in part selected due to initial concerns for GO-induced hepatotoxicity, particularly SOS when GO was given in close proximity to HCT.(31, 32) Although we did observe a few cases of SOS in the GO cohort, there was no apparent increase and the overall numbers are too low to draw any definitive conclusions. Patients in the GO cohort had significantly higher TRM overall, with the majority of deaths attributed to infection.
It is important to note that the TRM in the No-GO cohort was very low, with only 1 death, which occurred post-HCT. This very low TRM rate is atypical for the intensity of standard AML therapy and lower than what was seen in AAML03P1 and AAML0531 overall, where there were no observed differences in overall TRM for patients in the GO vs. No-GO cohorts. (6, 12) Importantly, half of the TRM events in our study occurred over 100 days from the last dose of GO, and do not immediately seem to be directly attributable to GO. Even among patients who received GO prior to HCT, the majority of TRM events also occurred at over 100 days following HCT. subsequent cytotoxic therapy and lead to significantly prolonged myelosuppression. This delayed hematopoietic recovery and prolonged neutropenia could be a potential contributor to the higher TRM seen in the GO cohort, which was largely due to infectious causes. We observed no differences in infection rates between the two cohorts overall, however it is possible that prolonged myelosuppression could contribute to increased morbidity and 
